Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the
            US FDA
            Adverse Events Reporting System pharmacovigilance database

Necrosis Factor Alpha ◽

The Us ◽

Pharmacovigilance Database ◽

Factor Alpha ◽

Us Fda ◽

Necrosis Factor ◽

Reduced Risk

Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database

Rheumatology ◽

10.1093/rheumatology/keu145 ◽

2014 ◽

Vol 53 (8) ◽

pp. 1465-1469 ◽

Cited By ~ 13

Author(s):

J. Bene ◽

G. Moulis ◽

M. Auffret ◽

G. Lefevre ◽

P. Coquerelle ◽

...

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Disproportionality Analysis ◽

Necrosis Factor Alpha ◽

Pharmacovigilance Database ◽

Factor Alpha ◽

Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.12385 ◽

2013 ◽

Vol 38 (4) ◽

pp. 388-396 ◽

Cited By ~ 44

Author(s):

P. Deepak ◽

D. J. Stobaugh ◽

M. Sherid ◽

H. Sifuentes ◽

E. D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Tumour Necrosis ◽

Reporting System ◽

Adverse Event Reporting System ◽

Adverse Event Reporting ◽

Necrosis Factor Alpha ◽

Event Reporting ◽

Factor Alpha ◽

Intracellular glutathione regulates tumour necrosis factor-alpha-induced p38 MAP kinase activation and RANTES production by human bronchial epithelial cells

Clinical & Experimental Allergy ◽

10.1046/j.1365-2222.2001.00967.x ◽

2001 ◽

Vol 31 (1) ◽

pp. 144-151 ◽

Cited By ~ 6

Author(s):

S. Hashimoto ◽

Y. Gon ◽

K. Matsumoto ◽

I. Takeshita ◽

T. Machino ◽

...

Keyword(s):

Tumour Necrosis ◽

P38 Map Kinase ◽

Human Bronchial Epithelial Cells ◽

Necrosis Factor Alpha ◽

Bronchial Epithelial ◽

Kinase Activation ◽

Factor Alpha ◽

Rantes Production ◽

Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice

European Journal of Neuroscience ◽

10.1046/j.1460-9568.2000.01348.x ◽

2000 ◽

Vol 12 (12) ◽

pp. 4447-4456 ◽

Cited By ~ 24

Author(s):

Rose-Marie Bluthe ◽

Sophie Laye ◽

Bruno Michaud ◽

Chantal Combe ◽

Robert Dantzer ◽

...

Keyword(s):

Tumour Necrosis ◽

Interleukin 1 ◽

Type I ◽

Sickness Behaviour ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Deficient Mice ◽

P3442 In vivo inhibition of tumour necrosis factor-alpha reverses mitochondrial dysfunction in pacing-induced cardiomyopathy: Insights into role of cytokines and heart failure progression

European Heart Journal ◽

10.1016/s0195-668x(03)96068-4 ◽

2003 ◽

Vol 24 (5) ◽

pp. 665

Author(s):

J MARINGARCIA

Keyword(s):

Heart Failure ◽

Mitochondrial Dysfunction ◽

Tumour Necrosis ◽

Necrosis Factor Alpha ◽

Heart Failure Progression ◽

Factor Alpha ◽

Short-term histopathological response to anti-tumour necrosis factor alpha therapy in patients with ulcerative colitis

10.26226/morressier.596dfd59d462b80292387586 ◽

2017 ◽

Author(s):

Diana-Alexandra Costache

Keyword(s):

Ulcerative Colitis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Short Term ◽

Histopathological Response ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Therapy ◽

Faculty Opinions recommendation of A role for tumour necrosis factor-alpha, complement C5 and interleukin-6 in the initiation and development of the mycobacterial cord factor trehalose 6,6'-dimycolate induced granulomatous response.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1120210.576363 ◽

2008 ◽

Author(s):

John Atkinson

Keyword(s):

Tumour Necrosis Factor ◽

Interleukin 6 ◽

Tumour Necrosis ◽

Necrosis Factor Alpha ◽

Cord Factor ◽

Factor Alpha ◽

Necrosis Factor ◽

Granulomatous Response

Faculty Opinions recommendation of Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162910.623534 ◽

2009 ◽

Author(s):

Ulf Müller-Ladner

Keyword(s):

Tumour Necrosis Factor ◽

Dose Escalation ◽

Inflammatory Arthritis ◽

Tumour Necrosis ◽

Phase 1 ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Alpha Antagonist ◽

Faculty Opinions recommendation of Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2695956.2359056 ◽

2010 ◽

Author(s):

Scott Davies

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Fungal Infections ◽

Inhibitor Therapy ◽

Necrosis Factor Alpha ◽

Factor Alpha ◽

Faculty Opinions recommendation of Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718325310.793492804 ◽

2014 ◽

Author(s):

Ronald van Vollenhoven

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis ◽

Active Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Human Antibody ◽

Necrosis Factor Alpha ◽

Subcutaneous Injections ◽

Factor Alpha ◽